Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Shares Issued (2016 - 2025)

United Therapeutics' Shares Issued history spans 17 years, with the latest figure at $4.3 million for Q3 2025.

  • For Q3 2025, Shares Issued fell 96.5% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $9.2 million, down 93.97%, while the annual FY2025 figure was $9.2 million, 93.97% down from the prior year.
  • Shares Issued for Q3 2025 was $4.3 million at United Therapeutics, up from -$11.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $122.9 million in Q3 2024 and bottomed at -$36.7 million in Q4 2021.
  • The 5-year median for Shares Issued is $4.3 million (2025), against an average of $12.0 million.
  • The largest annual shift saw Shares Issued crashed 259.29% in 2022 before it surged 3740.62% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$36.7 million in 2021, then skyrocketed by 39.24% to -$22.3 million in 2022, then surged by 114.35% to $3.2 million in 2023, then surged by 703.12% to $25.7 million in 2024, then plummeted by 83.27% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Shares Issued are $4.3 million (Q3 2025), -$11.7 million (Q2 2025), and $16.6 million (Q1 2025).